Michel Vounatsos has been Chief Executive Officer (CEO) of Biogen and a member of its Board of Directors since January 2017. He joined the company in 2016 as Executive Vice President, Chief Commercial Officer. Under Mr. Vounatsos’ direction, Biogen is pursuing its strategy as the leader in neuroscience. He has focused the company on neuroscience as well as adjacent therapeutic areas, underpinned by the belief that neurological diseases and treatment strategies are interconnected. This expertise has placed Biogen in a unique position to accelerate progress and pioneer innovative new therapies that will improve patient health. Mr. Vounatsos leads Biogen’s mission to build a multi-franchise portfolio with long-term growth potential across various therapeutic areas, including multiple sclerosis and spinal muscular atrophy (SMA). Recently, Biogen executed one of the most successful rare disease launches of all time with SPINRAZA, the first and only approved treatment for SMA.
Additionally, Mr. Vounatsos is helping transform society’s perspectives around aging by redefining what it means to grow old and age well. He’s also an advocate for increased collaboration across the healthcare system to ensure greater value and access to treatments for all patients and a shift toward more holistic patient solutions through digital medicine. Mr. Vounatsos is a strong supporter of Diversity & Inclusion and of building high-performing teams who are dedicated to making a difference in the lives of patients while maintaining the highest levels of ethics.
Prior to joining Biogen, Mr. Vounatsos had a 20-year career at Merck, where he notably transformed the company’s go-to-market model to meet the changing needs of customers and helped further grow the business both in mature and emerging markets. Previously, Mr. Vounatsos held management positions at Ciba-Geigy. He has been a member of the Board of PhRMA since 2017 and is a member of the MIT Presidential CEO Advisory Board. Mr. Vounatsos is also part of the Advisory Board at Tsinghua University, School of Pharmaceutical Sciences, in Beijing as well as the Chairman of the Administrative Board of the Liyrc Institute in Bordeaux.
After studying medicine and obtaining his Certificate of Clinical and Therapeutic Synthesis from Victor Segalen University, Bordeaux II, Mr. Vounatsos obtained an MBA from HEC Paris and continued his career in the industry, combining his passion for health and the search for new medicines.